Revlimid / dexamethasone (RevDex) as induction therapy prior to transplantation of peripheral blood progenitor cells for the treatment of patients with newly diagnosed multiple myeloma, Revlimid monotherapy followed by maintenance therapy. Comparison of two strategies for mobilization of peripheral blood progenitor cells [Revlimid/dexametasona (RevDex) como tratamiento de induccion previo al trasplante de celulas progenitoras de sangre periferica para el tratamiento de pacientes con mieloma multiple de nuevo diagnostico, seguido de Revlimid en monoterapia como tratamiento de mantenimiento. Comparacion de dos estrategias de movilizacion de celulas progenitoras de sangre periferica]

Trial Profile

Revlimid / dexamethasone (RevDex) as induction therapy prior to transplantation of peripheral blood progenitor cells for the treatment of patients with newly diagnosed multiple myeloma, Revlimid monotherapy followed by maintenance therapy. Comparison of two strategies for mobilization of peripheral blood progenitor cells [Revlimid/dexametasona (RevDex) como tratamiento de induccion previo al trasplante de celulas progenitoras de sangre periferica para el tratamiento de pacientes con mieloma multiple de nuevo diagnostico, seguido de Revlimid en monoterapia como tratamiento de mantenimiento. Comparacion de dos estrategias de movilizacion de celulas progenitoras de sangre periferica]

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Mar 2016

At a glance

  • Drugs Dexamethasone (Primary) ; Lenalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Mar 2016 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
    • 25 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top